Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer

Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer

Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer Today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization…

Read MorePersonalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer
CyPath® Lung Identifies Stage 1A Lung Cancer in High-Risk Patient Despite Inconclusive Imaging

CyPath® Lung Identifies Stage 1A Lung Cancer in High-Risk Patient Despite Inconclusive Imaging

BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company addressingthe need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in…

Read MoreCyPath® Lung Identifies Stage 1A Lung Cancer in High-Risk Patient Despite Inconclusive Imaging
Exact Sciences Secures Medicare Coverage for Oncodetect™ MRD Test in Colorectal Cancer

Exact Sciences Secures Medicare Coverage for Oncodetect™ MRD Test in Colorectal Cancer

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services…

Read MoreExact Sciences Secures Medicare Coverage for Oncodetect™ MRD Test in Colorectal Cancer
Arch Launches New Supplemental Health Insurance Plans to Close Coverage Gaps

Aptar’s Material Science Innovation Enhances Moisture and Oxygen Control for Drugs and Devices

A global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution…

Read MoreAptar’s Material Science Innovation Enhances Moisture and Oxygen Control for Drugs and Devices
Petspan Unveils First Telemedicine Protocol with Rapamycin for Treating Feline Hypertrophic Cardiomyopathy

Petspan Unveils First Telemedicine Protocol with Rapamycin for Treating Feline Hypertrophic Cardiomyopathy

Petspan, the veterinary telemedicine division of longevity health company Healthspan, today announced the launch of the industry’s first remote-care protocol delivering rapamycin therapy to cats diagnosed with hypertrophic cardiomyopathy (HCM). Our HCM protocol gives cat parents access to a therapy supported by…

Read MorePetspan Unveils First Telemedicine Protocol with Rapamycin for Treating Feline Hypertrophic Cardiomyopathy
OhioGuidestone Scales Use of Greenspace Health’s Platform to Improve Mental Health Care

OhioGuidestone Scales Use of Greenspace Health’s Platform to Improve Mental Health Care

OhioGuidestone, Ohio’s leader in community behavioral healthcare, announced today the expansion of its partnership with Greenspace Health, extending the use of its Measurement-Based Care (MBC) technology across the organization’s behavioral health services to further improve their quality of care, client outcomes…

Read MoreOhioGuidestone Scales Use of Greenspace Health’s Platform to Improve Mental Health Care
Cardio Diagnostics and AGEPHA Pharma Collaborate to Enhance Precision Care for Coronary Inflammation

Cardio Diagnostics and AGEPHA Pharma Collaborate to Enhance Precision Care for Coronary Inflammation

A precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease (CHD). Specifically, AGEPHA Pharma…

Read MoreCardio Diagnostics and AGEPHA Pharma Collaborate to Enhance Precision Care for Coronary Inflammation
Sarepta

AI Platform Evidently Announces Partnership With Allina Health

AI Platform Evidently Announces Partnership With Allina Health Clinical data intelligence platform Evidently is announcing an extended partnership with Allina Health, under which Evidently’s AI system will process millions of patient encounters each year to reduce clinicians’ cognitive workloads while elevating quality…

Read MoreAI Platform Evidently Announces Partnership With Allina Health